Centinel Spine Announces First Use of the Expanded prodisc C Family of Devices in US Clinical Study
- Posted on: Sep 3 2020
Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that the first implantation took place in an Investigational Device Exemption (IDE) study monitored by the Food and Drug Administration (FDA). The two-level IDE clinical trial is a prospective, randomized, multi-centered clinical study evaluating two different cervical total disc replacement (TDR) devices at multiple sites across the United States. Read more
After 18 months of training and validation, we have begun our clinical trial! Dr. Jason Tinley implanted the world’s first ProDisc SK and the first ProDisc Vivo in the United States in the same patient. Spine surgeons will have the ability to match the implant profile to the patient’s specific anatomy for the first time ever in Total Disc Replacement surgery.
Below are Tinley’s words on the experience:
“Nothing makes me happier than making people’s lives better through advancing technologies in spine surgery. Decompressing the spine while maintaining or improving motion with artificial disc replacement is a truly minimally-invasive, outpatient procedure that minimizes the chances of having healing issues or breakdown at other levels, and is the most gratifying procedure I do. This FDA trial for two-level ADR surgery with ProDisc is another advancement to keep people from needing multiple surgeries from our vertebrae being stacked on top of each other… Thrilled to be a part of change. DFW Center for Spinal Disorders
Posted in: Uncategorized